Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: Results of the Comparative HDL Efficacy and Safety Study (CHESS) - 28/08/11
, Michael A Blazing, MD b, Donald B Hunninghake, MD c, Michael H Davidson, MD d, Zhong Yuan, MD, PhD e, Paul DeLucca, PhD e, Karen E Ramsey, RPh e, Carolyn M Hustad, PhD e, Joanne Palmisano, MD eAbstract |
Background |
Previous studies have shown that effects on high-density lipoprotein cholesterol (HDL-C) may differ among statins.
Methods |
A multicenter, randomized, double-blind, parallel-dose study was conducted in 917 hypercholesterolemic patients to compare the efficacy of 80 mg/d simvastatin versus 80 mg/d atorvastatin on HDL-C and apolipoprotein (apo) A-I for 24 weeks. Efficacy was assessed as the means of weeks 6 and 12 and weeks 18 and 24. Prespecified subgroups analyzed were patients with low HDL-C levels and with the metabolic syndrome.
Results |
Simvastatin increased HDL-C and apo A-I values significantly more than did atorvastatin for the mean of weeks 6 and 12 (8.9% vs 3.6% and 4.9% vs −0.9%, respectively) and the mean of weeks 18 and 24 (8.3% vs 4.2% and 3.7% vs −1.4%). These differences were observed across both baseline HDL-C subgroups (<40 mg/dL, ≥40 mg/dL) and in patients with the metabolic syndrome. Low-density lipoprotein cholesterol and triglyceride reductions were greater with atorvastatin. Consecutive elevations >3× the upper limit of normal in alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) occurred in significantly fewer patients treated with simvastatin than with atorvastatin (2/453 [0.4%] vs 13/464 [2.8%]), with most elevations observed in women taking atorvastatin (11/209 [5.3%] vs 1/199 [0.5%] for simvastatin).
Conclusions |
Simvastatin (80 mg) increased HDL-C and apo A-I significantly more than did atorvastatin (80 mg) in patients with hypercholesterolemia. This advantage was observed regardless of HDL-C level at baseline or the presence of the metabolic syndrome. Significantly fewer consecutive elevations >3× the upper limit of normal in ALT and/or AST occurred in patients receiving simvastatin.
Le texte complet de cet article est disponible en PDF.Plan
 | Supported by a grant from Merck & Co, Inc, Whitehouse Station, NJ. Guest Editor for this manuscript was Christopher P. Cannon, MD, Brigham and Women’s Hospital, Boston Mass. |
Vol 146 - N° 5
P. 862-869 - novembre 2003 Retour au numéro
Article précédent
- 4G/5G polymorphism of the plasminogen activator inhibitor-1 gene and risk of restenosis after coronary artery stenting
- Corinna Böttiger, Werner Koch, Christina Lahn, Julinda Mehilli, Nicolas von Beckerath, Albert Schömig, Adnan Kastrati
- Lipid changes on hormone therapy and coronary heart disease events in the Heart and Estrogen/progestin Replacement Study (HERS)
- Michael G Shlipak, Lily A Chaput, Eric Vittinghoff, Feng Lin, Vera Bittner, Robert H Knopp, Stephen B Hulley, Heart and Estrogen/progestin Replacement Study (HERS) Investigators
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?